#### (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

# (19) World Intellectual Property Organization International Bureau





(43) International Publication Date 13 August 2009 (13.08.2009)

(10) International Publication Number WO 2009/099961 A3

- (51) International Patent Classification:

  C07K 16/00 (2006.01) C07K 19/00 (2006.01)

  C07K 16/10 (2006.01)
- (21) International Application Number:

PCT/US2009/032692

(22) International Filing Date:

30 January 2009 (30.01.2009)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

61/063,245 31 January 2008 (31.01.2008)

) US

- (71) Applicant (for all designated States except US): THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES [US/US]; National Institutes Of Health, Office Of Technology Transfer, 6011 Executive Blvd., Suite 325, Rockville, MD 20852-3804 (US).
- (72) Inventor; and
- (75) Inventor/Applicant (for US only): DIMITROV, Dimiter, S. [US/US]; 1019 Storrington Drive, Frederick, MD 21702 (US).
- (74) Agent: CONNOLLY, Jodi, L.; Klarquist Sparkman, LLP, One World Trade Center, Suite 1600, 121 Sw Salmon Street, Portland, OR 97204 (US).
- (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ,

CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

#### **Declarations under Rule 4.17:**

of inventorship (Rule 4.17(iv))

#### Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))
- with sequence listing part of description (Rule 5.2(a))
- (88) Date of publication of the international search report:

1 October 2009



(54) Title: ENGINEERED ANTIBODY CONSTANT DOMAIN MOLECULES

(57) Abstract: Described herein are engineered antibody constant domain molecules, such as CH2 or CH3 domain molecules, comprising at least one mutation, or comprising at least one complementarity determining region (CDR), or a functional fragment thereof, engrafted in a loop region of the CH2 domain. The CH2 domain molecules described herein are small, stable, soluble, exhibit little to no toxicity and are capable of binding antigen.

International application No PCT/US2009/032692

A. CLASSIFICATION OF SUBJECT MATTER
INV. C07K16/00 C07K16/10 C07K19/00 According to International Patent Classification (IPC) or to both national classification and IPC **B. FIELDS SEARCHED** Minimum documentation searched (classification system followed by classification symbols) C07K Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched Electronic data base consulted during the international search (name of data base and, where practical, search terms used) EPO-Internal, BIOSIS, EMBASE C. DOCUMENTS CONSIDERED TO BE RELEVANT Category\* Citation of document, with indication, where appropriate, of the relevant passages Relevant to claim No. X WO 2006/072620 A (RUEKER FLORIAN [AT]; 1-8, WOZNIAK-KNOPP GORDANA [AT]) 12 - 31, 13 July 2006 (2006-07-13) 43,44, 46-62,64 examples 1-10 claim 30 page 29, line 2 - line 10 page 41 χ WO 2006/114700 A (BIOREN INC [US]; CREA 43,44, ROBERTO [US]; CAPPUCCILLI GUIDO [US]; 47,48 TAKEUCHI T) 2 November 2006 (2006-11-02) sequences 1,12 X US 2007/148170 A1 (DESJARLAIS JOHN R [US] 43,44, ET AL) 28 June 2007 (2007-06-28) 47,48 sequences 25-27 -/--|X | Further documents are listed in the continuation of Box C. See patent family annex. Special categories of cited documents: \*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the \*A\* document defining the general state of the art which is not considered to be of particular relevance invention \*E\* earlier document but published on or after the international \*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) \*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such docu-\*O\* document referring to an oral disclosure, use, exhibition or other means ments, such combination being obvious to a person skilled in the art. document published prior to the international filing date but later than the priority date claimed \*&\* document member of the same patent family Date of the actual completion of the international search Date of mailing of the international search report 17 July 2009 03/08/2009 Name and mailing address of the ISA/ Authorized officer European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Bumb, Peter Fax: (+31-70) 340-3016

International application No.

PCT/US2009/032692

Вох	No. I	Nucleotide and/or amino acid sequence(s) (Continuation of item 1.b of the first sheet)
1.	With inven	regard to any nucleotide and/or amino acid sequence disclosed in the international application and necessary to the claimed tion, the international search was carried out on the basis of:
	a.	type of material  X a sequence listing table(s) related to the sequence listing
	b.	format of material  X on paper  X in electronic form
	<b>c.</b>	time of filing/furnishing  X contained in the international application as filed  X filed together with the international application in electronic form  furnished subsequently to this Authority for the purpose of search
2.		In addition, in the case that more than one version or copy of a sequence listing and/or table relating thereto has been filed or furnished, the required statements that the information in the subsequent or additional copies is identical to that in the application as filed or does not go beyond the application as filed, as appropriate, were furnished.
3.	Additi	ional comments:

International application No PCT/US2009/032692

C(C==t!=:		C1/US2009/032692
<del></del>	tion). DOCUMENTS CONSIDERED TO BE RELEVANT	
X	WO 2007/076319 A (CENTOCOR INC [US];	Relevant to claim No.
	O'NEIL KARYN T [US]; PICHA KRISTEN [US]; STOJANOVIC) 5 July 2007 (2007-07-05) sequences 43,45	47,48
X	US 2005/136049 A1 (LEDBETTER JEFFREY A [US] ET AL) 23 June 2005 (2005-06-23) page 113, line 29 - line 32	43,44, 47,48
X	US 5 965 709 A (PRESTA LEONARD G [US] ET AL) 12 October 1999 (1999-10-12) sequence 60	43,44, 47,48
Ρ,Χ	WO 2008/100470 A (TRANSTECH PHARMA INC [US]; MJALLI ADNAN M M [US]; TIAN YE E [US]; WEBS) 21 August 2008 (2008-08-21) sequence 14 figure 1E	43,44, 47,48
P,X	WO 2008/153745 A (AMGEN INC [US]; WALKER KENNETH W [US]; GEGG COLIN V JR [US]) 18 December 2008 (2008-12-18) sequences 1, 107, 108 page 26	43,44, 47,48
A	WO 2006/036834 A (AMGEN INC [US]) 6 April 2006 (2006-04-06) page 74 examples 1,13	
A	FEIGE M J ET AL: "Folding Mechanism of the CH2 Antibody Domain" JOURNAL OF MOLECULAR BIOLOGY, LONDON, GB, vol. 344, no. 1, 12 November 2004 (2004-11-12), pages 107-118, XP004609207 ISSN: 0022-2836 cited in the application the whole document	
A	THIES M J W ET AL: "The alternatively folded state of the antibody CH3 domain" JOURNAL OF MOLECULAR BIOLOGY, LONDON, GB, vol. 309, no. 5, 22 June 2001 (2001-06-22), pages 1077-1085, XP004479201 ISSN: 0022-2836 the whole document	
	-/	

International application No
PCT/US2009/032692

A IHIES M J W ET AL: "Folding and Oxidation of the Antibody Domain CH3" JOURNAL OF MOLECULAR BIOLOGY, LONDON, GB, vol. 319, no. 5, 21 June 2002 (2002-06-21), pages 1267-1277, XP004449701 ISSN: 0022-2836 the whole document  A US 6 277 375 B1 (WARD ELIZABETH SALLY [US]) 21 August 2001 (2001-08-21) column 31, line 35 - line 38 column 46, line 43 - column 47, line 32  A SKERRA A: "ENGINEERED PROTEIN SCAFFOLDS FOR MOLECULAR RECOGNITION, HEYDEN & SON LTD., LONDON, GB, vol. 13, no. 4, 1 July 2000 (2000-07-01), pages 167-187, XP009019725 ISSN: 0952-3499 the whole document  A LIPOVSEK ET AL: "Evolution of an Interloop Disulfide Bond in High-Affinity Antibody Mimics Based on Fibronectin Type III Domain and Selected by Yeast Surface Display: Molecular Convergence with Single-Domain Camelid and Shark Antibodies" JOURNAL OF MOLECULAR BIOLOGY, LONDON, GB, vol. 368, no. 4, 17 April 2007 (2007-04-17), pages 1024-1041, XP022030013 ISSN: 0022-2836 the whole document  P,A GONG RUI ET AL: "Engineered human antibody constant domains with increased	C(Continua	ation). DOCUMENTS CONSIDERED TO BE RELEVANT	PC1/052009/032692
of the Antibody Domain CH3"  JOURNAL OF MOLECULAR BIOLOGY, LONDON, GB, vol. 319, no. 5, 21 June 2002 (2002-06-21), pages 1267-1277, XPD04449701  ISSN: 0022-2836 the whole document  A US 6 277 375 B1 (WARD ELIZABETH SALLY [US]) 21 August 2001 (2001-08-21) column 31, line 35 - line 38 column 46, line 43 - column 47, line 32			Relevant to claim No.
[US]) 21 August 2001 (2001-08-21) column 31, line 35 - line 38 column 46, line 43 - column 47, line 32  A SKERRA A: "ENGINEERED PROTEIN SCAFFOLDS FOR MOLECULAR RECOGNITION" JOURNAL OF MOLECULAR RECOGNITION, HEYDEN & SON LTD., LONDON, GB, vol. 13, no. 4, 1 July 2000 (2000-07-01), pages 167-187, XP009019725 ISSN: 0952-3499 the whole document  A LIPOVSEK ET AL: "Evolution of an Interloop Disulfide Bond in High-Affinity Antibody Mimics Based on Fibronectin Type III Domain and Selected by Yeast Surface Display: Molecular Convergence with Single-Domain Camelid and Shark Antibodies" JOURNAL OF MOLECULAR BIOLOGY, LONDON, GB, vol. 368, no. 4, 17 April 2007 (2007-04-17), pages 1024-1041, XP022030013 ISSN: 0022-2836 the whole document  P,A GONG RUI ET AL: "Engineered human antibody constant domains with increased	A	of the Antibody Domain CH3" JOURNAL OF MOLECULAR BIOLOGY, LONDON, GB, vol. 319, no. 5, 21 June 2002 (2002-06-21), pages 1267-1277, XP004449701 ISSN: 0022-2836	
FOR MOLECULAR RECOGNITION" JOURNAL OF MOLECULAR RECOGNITION, HEYDEN & SON LTD., LONDON, GB, vol. 13, no. 4, 1 July 2000 (2000-07-01), pages 167-187, XP009019725 ISSN: 0952-3499 the whole document   A LIPOVSEK ET AL: "Evolution of an Interloop Disulfide Bond in High-Affinity Antibody Mimics Based on Fibronectin Type III Domain and Selected by Yeast Surface Display: Molecular Convergence with Single-Domain Camelid and Shark Antibodies" JOURNAL OF MOLECULAR BIOLOGY, LONDON, GB, vol. 368, no. 4, 17 April 2007 (2007-04-17), pages 1024-1041, XP022030013 ISSN: 0022-2836 the whole document  P,A GONG RUI ET AL: "Engineered human antibody constant domains with increased	A	[US]) 21 August 2001 (2001-08-21) column 31, line 35 - line 38	
Interloop Disulfide Bond in High-Affinity Antibody Mimics Based on Fibronectin Type III Domain and Selected by Yeast Surface Display: Molecular Convergence with Single-Domain Camelid and Shark Antibodies" JOURNAL OF MOLECULAR BIOLOGY, LONDON, GB, vol. 368, no. 4, 17 April 2007 (2007-04-17), pages 1024-1041, XP022030013 ISSN: 0022-2836 the whole document  P,A GONG RUI ET AL: "Engineered human antibody constant domains with increased	A	FOR MOLECULAR RECOGNITION" JOURNAL OF MOLECULAR RECOGNITION, HEYDEN & SON LTD., LONDON, GB, vol. 13, no. 4, 1 July 2000 (2000-07-01), pages 167-187, XP009019725 ISSN: 0952-3499	
antibody constant domains with increased	A	Interloop Disulfide Bond in High-Affinity Antibody Mimics Based on Fibronectin Type III Domain and Selected by Yeast Surface Display: Molecular Convergence with Single-Domain Camelid and Shark Antibodies"  JOURNAL OF MOLECULAR BIOLOGY, LONDON, GB, vol. 368, no. 4, 17 April 2007 (2007-04-17), pages 1024-1041, XP022030013 ISSN: 0022-2836	
THE JOURNAL OF BIOLOGICAL CHEMISTRY 22 MAY 2009, vol. 284, no. 21, 22 May 2009 (2009-05-22), pages 14203-14210, XP002537697 ISSN: 0021-9258 the whole document	P , A	antibody constant domains with increased stability." THE JOURNAL OF BIOLOGICAL CHEMISTRY 22 MAY 2009, vol. 284, no. 21, 22 May 2009 (2009-05-22), pages 14203-14210, XP002537697 ISSN: 0021-9258	1-64

International application No. PCT/US2009/032692

# INTERNATIONAL SEARCH REPORT

Box No. II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)
This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:
1. Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely:
Claims Nos.:  because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).
Box No. III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)
This International Searching Authority found multiple inventions in this international application, as follows:
see additional sheet
1. As all required additional search fees were timely paid by the applicant, this international search report covers allsearchable claims.
2. As all searchable claims could be searched without effort justifying an additional fees, this Authority did not invite payment of additional fees.
3. As only some of the required additional search fees were timely paid by the applicant, this international search reportcovers only those claims for which fees were paid, specifically claims Nos.:
4. No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:
The additional search fees were accompanied by the applicant's protest and, where applicable, the payment of a protest fee.  The additional search fees were accompanied by the applicant's protest but the applicable protest fee was not paid within the time limit specified in the invitation.
No protest accompanied the payment of additional search fees.

#### FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. claims: 1-35, 49-59 (all complete), 60, 64 (both in part)

Introduction of mutations or CDR into loops of CH2 or CH3 in order to provide an antigen binding polypeptide.

2. claims: 36-42, 63 (all complete); 60, 64 (both in part)

Introduction of an additional disulfide bridge into CH2 or CH3 in order to increase stability.

3. claims: 43-48, 61-62 (all complete); 60, 64 (both in part)

Truncation (i.e. by the full 7 amino acids) of CH2 or CH3 without antigen-binding activity in order to provide monomeric domains with improved stability

Information on patent family members

International application No
PCT/US2009/032692

Patent do- cited in sear			Publication date		Patent lamily member(s)		Publication date
WO 2006	072620	A	13-07-2006	AT	423140	T	15-03-2009
			-	ΑT	414718		15-12-2008
				ΑT	425186		15-03-2009
				ΑU	2006204459	A1	13-07-2006
				BR	PI0606399	A2	23-06-2009
				CA	2594356	A1	13-07-2006
				CN	101098891	Α	02-01-2008
				DK	1772465	T3	25-05-2009
				DK	1752471	T3	16-03-2009
				DK	1699826	T3	06-07-2009
				EΑ	200701443	A1	28-02-2008
				EΡ	1772465	A1	11-04-2007
				EP	1752471		14-02-2007
				EP	1699826	A1	13-09-2006
				EP	2028193		25-02-2009
				ES	2321861		12-06-2009
				ES	2320374		21-05-2009
				HR	20090087		31-03-2009
				HR	20090228		31-05-2009
				JP	2008526809		24-07-2008
				KR	20070092242		12-09-2007
				SI	1752471	_	30-04-2009
				SI	1772465	T1 	30-06-2009
WO 2006	114700	Α	02-11-2006	CA	2605697	A1	02-11-2006
				EΡ	1877441		16-01-2008
				JP	2008538908	T	13-11-2008
US 2007	 148170	A1	28-06-2007	AU	2006299429	 Δ1	12-04-2007
00 2007	1401/0	/\ <b>-</b>	20 00 2007	CA	2624189		12-04-2007
				EP	1931709		18-06-2008
				ŪS	2008206867		28-08-2008
				WO	2007041635		12-04-2007
WO 2007	 076319	 A	05-07-2007	CA	2634784	 Δ1	05-07-2007
WO 2007	0/0319	^	05-07-2007	EP	1968645		17-09-2008
US 2005	136049 	A1	23-06-2005	NON	E 		
US 5965	709	Α	12-10-1999	NON	E		
WO 2008	 100470	Α	21-08-2008	AR	065373	A1	03-06-2009
		. •		CL	4602008		22-08-2008
				ÜS	2008199467		21-08-2008
				ŪΫ́	30925		30-09-2008
WO 2008	 153745	Α	18-12-2008	US	2009118181	A1	07-05-2009
HO 2000							
WO 2006	U3 <b>0</b> 834	Α	06-04-2006	AU	2005289685		06-04-2006
				BR	PI0516011		19-08-2008
				CA	2580796		06-04-2006
				CN	101103045		09-01-2008
				EA EP	200700623 1797127		28-12-2007
				JP	2008514201		20-06-2007 08-05-2008
				KR	20070057975		08-05-2008
				· / //			0/-00-200/
						A1	25-07-2002